Wednesday, 18 November 2026

Some users see a 2–3 year age drop on GLP-1 weight-loss drugs

Lilly and Novo say aging clocks read two to three years younger in patients on their drugs. The catch: only people with obesity or diabetes were studied.

Eli Lilly, related to: Some users see a 2–3 year age drop on GLP-1 weight-loss drugs
Photo: Kavali Chandrakanth KCK / CC BY-SA 4.0 (modified)

The short version

  • Eli Lilly and Novo Nordisk say patients on their GLP-1 drugs scored about two to three years younger on molecular aging clocks than those on placebo.
  • Novo's study drew blood from 10,052 people; one heart-protein clock showed a gap of as much as four years.
  • The studies covered only people who were overweight or had diabetes, so the effect in healthy people is unknown.
  • Known side effects include stomach problems, pancreatitis and gallstones, with open questions about eyes, hair, nails and children.
Quick read · 1 min

Eli Lilly and Novo Nordisk say patients on their GLP-1 weight-loss drugs scored about two to three years younger on molecular "aging clocks" than similar patients on placebo. Novo's study drew blood from 10,052 people; one heart-protein clock showed a gap of up to four years. Lilly's smaller study of tirzepatide found a similar pattern.

The catch is that everyone studied was overweight or had diabetes. Nobody knows whether healthy people would see any effect, and the results come from the companies themselves.

  • About 11% of Americans now take a GLP-1 for weight loss.
  • Side effects include stomach problems, pancreatitis and gallstones.
  • The WHO advises against drug treatment for obesity in children under 10.

If you're healthy, these results aren't a reason to start taking one.

The best-selling drugs in the world may be doing something besides shrinking waistlines. Eli Lilly and Novo Nordisk, the companies behind Mounjaro, Zepbound, Ozempic and Wegovy, say patients taking their GLP-1 weight-loss drugs look about two to three years younger on lab tests that estimate biological age.

That’s a big claim for a class of drugs that a growing share of Americans already use. In a recent Gallup poll, 11% of American adults said they currently use one of these drugs to lose weight. That share was 3% in 2024, and 15% say they have tried one at some point. But there’s an important limit hiding in the headline, and the list of side effects is still being written.

01

What the GLP-1 weight-loss drugs studies found

Both companies presented their results in early October at Aging Research and Drug Discovery, a Boston conference focused on treatments for aging. They compared overweight or diabetic patients on the drugs with similar patients on a placebo, and in both cases the people on the drugs scored younger.

  • Novo Nordisk tested semaglutide, the drug in Ozempic and Wegovy. It took blood from 10,052 people, half on the drug and half on placebo, at the start of its trial and again months later. Measured with protein-based clocks, the gap was around two to three years overall, and as much as four years on a clock that reads heart proteins.
  • Eli Lilly tested tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, using clocks that read chemical changes on DNA. Its study was smaller, but it also found that for the most part, people on the drug aged more slowly by these measures.

Lilly’s head of aging research put it modestly: nobody is turning back the clock by decades, but the drop is significant. The results varied widely depending on which clock was used and which organ was measured.

Novo Nordisk, related to: Some users see a 2–3 year age drop on GLP-1 weight-loss drugs
Photo: Johan Wessman / News Oresund / CC BY 2.0 (modified)
02

What is biological age, anyway?

Your birthday tells you your age in years. Biological age tries to estimate how worn your body is. Scientists build “aging clocks” from things that change predictably over a lifetime, such as chemical tags on DNA or levels of certain proteins in the blood, and use them to predict how old someone’s body looks and, in some versions, their risk of dying.

Until now, nobody was sure these clocks meant much in practice. That’s why researchers in the field were excited: drugs with well-proven health benefits moved the clocks in the right direction. The UCLA professor credited with inventing aging clocks called a two-year difference a strong effect and said it hints the drugs could slow aging itself, not just treat weight.

03

The big catch: only unhealthy patients were tested

Every person in these studies was overweight or had diabetes. GLP-1 drugs already improve kidney function, lower blood pressure and sharply reduce the overall risk of death in those groups, so a younger reading on an aging clock may simply reflect a sick body getting healthier.

A Harvard biologist who helped with Novo’s measurements said he thinks the drugs act as an anti-aging treatment in an unhealthy population, but that in healthy people “no one knows.” When the conference organizer, who said he takes small doses of both drugs despite not being overweight, asked a Novo scientist whether a reasonable person should start semaglutide, the scientist said he wasn’t a physician and couldn’t answer.

It’s also worth remembering who ran these studies. The findings come from the two companies that sell the drugs, and they were shared as conference presentations, so treat them as early results.

Living room with cane, yoga mat and medicine bottle suggesting lifestyle changes
04

The side effects we’re still learning about

Like any drug, GLP-1s have downsides, and some are still coming into focus.

  • Common: stomach trouble is the big one, including constipation, diarrhea, vomiting and nausea.
  • Serious but less common: the drugs have been linked to gallstone disease and pancreatitis. Muscle loss is another concern researchers raise.
  • Eyes: dozens of people are suing Novo and Lilly, claiming the drugs caused a condition affecting nerves behind the eye that can lead to sudden vision loss. Both companies dispute this, and research on the link is mixed.
  • Hair and nails: an analysis of health records from 67 US health-care organizations linked GLP-1 use to a higher risk of hair loss, though it isn’t thought to be common. A smaller study found 66% of users reported at least one nail problem, but nail problems were also fairly common in people not taking the drugs, and the authors didn’t claim the drugs caused them.
05

What this means for you if you take a GLP-1, or want to

If you’re already on one of these drugs for obesity or diabetes, the aging research is a possible bonus on top of benefits doctors already know about. It doesn’t change why you take it, and side effects still deserve a conversation with your doctor.

If you’re healthy and wondering about taking one to stay young, the evidence isn’t there. No study has shown these drugs slow aging in people without weight or blood sugar problems, and side effects like muscle loss could outweigh any benefit. Even the UCLA clock pioneer says he isn’t ready to take them himself.

Parents should be extra careful. Prescriptions for children aged eight to 11 with obesity in the US rose 310-fold between 2019 and 2026, though they are still rare, and there is little data on side effects in kids. The World Health Organization’s first guidelines on managing childhood obesity, released in early October, say it does not recommend drug treatment for children under 10, citing a lack of evidence on effects on growth, development and mental health.

06

Quick answers

Do GLP-1 drugs reverse aging?

In drugmaker studies of people with obesity or diabetes, those on the drugs scored about two to three years younger on aging clocks than people on placebo. Whether that means slower aging in healthy people is unknown.

Which GLP-1 drugs were studied?

Novo Nordisk’s semaglutide, sold as Ozempic and Wegovy, and Eli Lilly’s tirzepatide, sold as Mounjaro and Zepbound.

What are the most common GLP-1 side effects?

Stomach problems such as nausea, vomiting, diarrhea and constipation. Pancreatitis and gallstones are rarer but more serious risks.

You're reading the quick version.